Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-45,600
Closed -$7.94M 10818
2025
Q4
$7.94M Sell
45,600
-2,600
-5% -$474K ﹤0.01% 3544
2025
Q3
$6.94M Sell
48,200
-41,800
-46% -$5.12M ﹤0.01% 3691
2025
Q2
$9.06M Buy
90,000
+79,400
+749% +$6.07M ﹤0.01% 3179
2025
Q1
$809K Sell
10,600
-81,600
-89% -$6.24M ﹤0.01% 5463
2024
Q4
$6.37M Sell
92,200
-36,000
-28% -$2.59M ﹤0.01% 3558
2024
Q3
$9.36M Hold
128,200
﹤0.01% 2432
2024
Q2
$8.59M Buy
+128,200
New +$4.97M ﹤0.01% 2348

Other funds holding INSM

UBS Group's INSM Position: Q2 2026 in Review

UBS Group increased its Insmed (INSM) stake by 49% in Q2 2026, buying an estimated $103M and bringing the position to 2,584,446 shares worth $276M. The position accounts for 0.04% of the portfolio, ranked #508.

UBS Group first reported a position in INSM in Q4 2014 and has held it in 47 quarters since. The position peaked at $325M in Q4 2025. 666 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

  • UBS Group held 2,584,446 shares of Insmed worth $276M as of Q2 2026.
  • UBS Group bought 846,965 Insmed shares in Q2 2026, an estimated $103M.
  • Insmed made up 0.04% of UBS Group's portfolio in Q2 2026, its #508 holding.
  • UBS Group first reported a position in Insmed in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Insmed position peaked at $325M in Q4 2025.
  • 666 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.